2026 ASCO® Annual Meeting

No Patient Left Behind: AI, Diagnostic Insights and Foundation Models that Challenge the Status Quo*

Discover how our comprehensive diagnostic intelligence platform transforms vast datasets into insights to ensure that no patient is left behind in the pursuit of better outcomes. Beyond the clinic, our foundation models redefine the R&D landscape—de-risking discovery and accelerating drug development.

Add to calendar

*Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Stop by our booth to experience live demos of our latest technologies and discover how we are leveraging Al to advance precision medicine.

Tempus Hub

Streamline ordering and get quick access to patient information through our secure online platform. Place orders tailored to your patient’s diagnosis with one-click, view comprehensive smart reports, receive automatic therapy match updates when new options emerge, and review patient medical history—all on one intelligent platform.

Tempus One

Get real-time answers and uncover patient insights with our generative AI assistant built for healthcare providers and researchers. Just ask a question to access data-driven responses instantly.



Tempus Lens

Quickly find, access, and analyze multimodal de-identified data records and uncover critical insights to accelerate research and innovation. Leverage our Al assistant, Tempus One, to quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets in seconds. Explore unstructured clinical data and extract nuanced insights.



Tempus Next Pathways

An AI-enabled care pathway platform that enables providers to deliver the Next step in a cancer patient’s care journey. Leverage the Next Platform, designed to surface deep insights from multimodal, longitudinal patient data including medical imaging data, EHR data, lab results, pathology reports and clinician notes.

Impact of the Taylor Cancer Research Center (TCRC) and Tempus AI TIME Partnership on Clinical Trial Start-up and Accrual

Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success

AI-driven RNA-based Homologous Recombination Deficiency algorithm predicts first-line platinum response in metastatic pancreatic cancer.

Screening for intrinsic and acquired resistance mutations to anti-EGFR in real-world MSS colorectal cancer data

KMT2C mutation identifies an immunotherapy-sensitive subset of gastrointestinal cancers: a large real-world analysis

Evaluation of homologous recombination deficiency (HRD) in gastric cancer: Real-world prevalence and outcomes with first-line (1L) platinum-based therapy

A new HLA genotyping algorithm shows extremely high accuracy and concordance between tumor and normal samples.

Development and clinical utility of an H&E-based tumor origin prediction model

ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy

Target-specific therapy for actionable and approved tumor-agnostic biomarkers: Influence on survival in rare cancers

First-Line Lenvatinib Versus Dabrafenib plus Trametinib (D+T) in BRAF-Mutated Differentiated Thyroid Cancer (DTC): Insights from Real-World Data

Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors

Multiomic machine learning integration of DNA and RNA to predict immunotherapy benefit in advanced MSS-CRC and rare cancers

Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): a translational analysis of the AtezoTRIBE study

Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing

Impact of FGFR3 Pathway Activation in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy

Improved Clinical outcomes with ERBB2 gene amplification and activating mutations in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy

Molecular Classification of Neuroendocrine Carcinoma of the Bladder

Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Actionable genomic alterations and outcomes in lung squamous and adenosquamous cell carcinoma

GEMINI-NSCLC: Multiomics and single-cell spatial profiling to benchmark, back-translate, and build digital twins of IO response

Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome

AQUARIUS: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients with Hematologic Malignancies

Concurrent RNA- and DNA-NGS testing for the detection of clinically-relevant fusions in pediatric solid-tumor patients

Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (mBC)

GEMINI-BREAST: Evaluating Minimal Residual Disease (MRD) through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Biology-informed predictive modeling and resistance monitoring in trastuzumab deruxtecan–treated metastatic breast cancer